BHV 8000
Alternative Names: BHV-8000; TLL-041Latest Information Update: 16 May 2024
At a glance
- Originator Hangzhou Highlightll Pharmaceutical
- Developer Biohaven Pharmaceuticals
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease; CNS disorders; Multiple sclerosis; Parkinson's disease
Most Recent Events
- 09 May 2024 Bioheaven plans to initiate phase II SAD/MAD studies in healthy volunteers in second half of 2024
- 08 Feb 2024 Phase-I clinical trials in Alzheimer's disease (Prevention) (PO) prior to February 2024 (Biohaven Pharmaceuticals pipeline, February 2024)
- 08 Feb 2024 Phase-I clinical trials in Alzheimer's disease (PO) prior to February 2024 (Biohaven Pharmaceuticals pipeline, February 2024)